Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug1851 | IIBR-100 high-dose (prime) Wiki | 0.38 |
| drug1860 | INC424 / Ruxolitinib Wiki | 0.38 |
| drug3432 | SARS-CoV-2 non-immune Plasma Wiki | 0.38 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug1853 | IIBR-100 medium dose (prime) Wiki | 0.38 |
| drug1859 | INB03 Wiki | 0.38 |
| drug302 | Anti- SARS-CoV-2 Plasma Wiki | 0.38 |
| drug2438 | Moxibustion plus Cupping Wiki | 0.38 |
| drug1854 | IIBR-100, low dose (prime) Wiki | 0.38 |
| drug1861 | INM005 Wiki | 0.38 |
| drug1844 | IC14 Wiki | 0.38 |
| drug1852 | IIBR-100 low-dose (prime-boost) Wiki | 0.38 |
| drug1848 | ID NOW vs. Accula Wiki | 0.38 |
| drug1857 | IMU-838 Wiki | 0.27 |
| drug3505 | Saline Placebo Wiki | 0.22 |
| drug1060 | Convalescent plasma Wiki | 0.16 |
| drug4441 | convalescent plasma Wiki | 0.15 |
| drug2729 | Oseltamivir Wiki | 0.14 |
| drug2916 | Placebo Wiki | 0.05 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| D018352 | Coronavirus Infections NIH | 0.04 |
| D045169 | Severe Acute Respiratory Syndrome NIH | 0.02 |
| Name (Synonyms) | Correlation |
|---|
Navigate: Correlations HPO
There are 7 clinical trials
Evaluate the efficacy of treatment with high-titer Anti- SARS-CoV-2 plasma versus control (SARS-CoV-2 non-immune plasma) in subjects exposed to Coronavirus disease (COVID-19) at day 28.
Description: Comparison of proportions of cumulative incidence of development of SARS-Cov-2 infection (symptoms compatible with infection and/or + molecular testing) regardless of disease severity, following high-titer Anti- SARS-CoV-2 plasma versus control (SARS-CoV-2 non-immune plasma) in subjects exposed to COVID-19.
Measure: Efficacy of treatment at Day 28 Time: Day 28Description: Cumulative incidence of serious adverse events categorized separately as either severe infusion reactions and Acute Respiratory Distress Syndrome during the study period.
Measure: Safety of treatment with high-titer Anti- SARS-CoV-2 plasma versus control - 1 Time: Up to Day 28Description: Cumulative incidence of grade 3 and 4 adverse events during the study period
Measure: Safety of treatment with high-titer Anti- SARS-CoV-2 plasma versus control - 2 Time: Up to Day 28Description: Cumulative incidence of disease severity between the anti-SARS-CoV-2 convalescent plasma and control groups after individuals develop SARS-CoV-2 infection. Severity of disease will be measured using a clinical event scale of disease severity (evaluated up to Day 28): Death Requiring mechanical ventilation and/or in ICU non-ICU hospitalization, requiring supplemental oxygen; non-ICU hospitalization, not requiring supplemental oxygen; Not hospitalized, but with clinical and laboratory evidence of COVID-19 infection
Measure: Cumulative incidence of disease severity Time: up to Day 28Description: Compare the anti-SARS-CoV-2 convalescent plasma and control (SARS-CoV-2 non-immune plasma) groups' anti-SARS-CoV-2 titers at day -1 or day 0 (baseline).
Measure: Anti-SARS-CoV-2 titers Day 0 Time: Day 0Description: Compare the anti-SARS-CoV-2 convalescent plasma and control (SARS-CoV-2 non-immune plasma) groups' anti-SARS-CoV-2 titers at day 1.
Measure: Anti-SARS-CoV-2 titers Day 1 Time: Day 1Description: Compare the anti-SARS-CoV-2 convalescent plasma and control (SARS-CoV-2 non-immune plasma) groups' anti-SARS-CoV-2 titers at day 7.
Measure: Anti-SARS-CoV-2 titers Day 7 Time: Day 7Description: Compare the anti-SARS-CoV-2 convalescent plasma and control (SARS-CoV-2 non-immune plasma) groups' anti-SARS-CoV-2 titers at day 14.
Measure: Anti-SARS-CoV-2 titers Day 14 Time: Day 14Description: Compare the anti-SARS-CoV-2 convalescent plasma and control (SARS-CoV-2 non-immune plasma) groups' anti-SARS-CoV-2 titers at day 90.
Measure: Anti-SARS-CoV-2 titers Day 90 Time: Day 90Description: Compare the rates of SARS-CoV-2 PCR positivity (RT-PCR) amongst the anti-SARS-CoV-2 convalescent plasma and control (SARS-CoV-2 non-immune plasma) groups at days 0, 7, 14 and 28.
Measure: Rates of SARS-CoV-2 PCR positivity Time: Up to day 28Description: Compare the duration (days) of SARS-CoV-2 PCR positivity (RT-PCR) amongst the anti-SARS-CoV-2 convalescent plasma and control (SARS-CoV-2 non-immune plasma) groups at days 0, 7, 14 and 28.
Measure: Duration of SARS-CoV-2 PCR positivity Time: Up to day 28Description: Compare the peak quantity levels of SARS-CoV-2 RNA amongst the anti-SARS-CoV-2 convalescent plasma and control (SARS-CoV-2 non-immune plasma) groups at days 0, 1, 7, 14 and 28 days.
Measure: Peak quantity levels of SARS-CoV-2 RNA Time: Up to day 28The present study will try to respond first in an initial phase, what is the minimum effective dose necessary of convalescent plasma for getting better in severly ill (not intubated) or very severely ill (intubated) patients. Once the dose will be determined by each type of patient group (severely ill vs. very severely ill) has been determined, phase 2 of the study will begin, where the safety and efficacy of the use of plasma will be evaluated based on clinical, imaging and laboratory criteria. So, our hypotheses are: 1. Is there a minimum effective dose to treat seriously ill patients with convalescent plasma with COVID-19? 2. the plasma dose with the minimum effective effect will improve the clinical, laboratory and clearance conditions of the presence of the virus in the severely ill patient?
Description: no fever, respiratory improvement and blood oxygenation (Sat02, Sat02 / Fi02), general laboratory improvement.
Measure: Clinical improvement Time: day -1 to day +22Description: before convalescent plasma infusion, the CT image will be compared and subsequently the evolution of images in the CT will be evaluated every 72 hours on 3 times .
Measure: improvement in tomographic image Time: day -1 to day +12Description: the patients will be evaluated on three occasions the positivity of the test (PCR-RT). If two of them are negative, it will be defined as a virus-free patient.
Measure: test positivity for COVID-19 Time: day +6 to day +12Description: Patients will be evaluated for adverse events during the plasma infusion up to 30 days after that. Especially mild and severe allergic reactions (anaphylaxis), other issues like TRALI.
Measure: early and late complications associated to convalescent plasma Time: day 0 to day +30Description: days of stay at ICU will be evaluated
Measure: days at ICU Time: day 0 to day +30This trial is designed to evaluate the efficacy and safety of moxibustion plus cupping in the convalescence of COVID-19.
Description: At the end of week 4, the average visual analogue scale (VAS) score of main clinical symptoms in the past 1 week changed from baseline. The VAS score ranges from 0 to 100 point and the higher scores mean worse symptoms (The main clinical symptoms including: Cough /chest tightness/shortness of breath after exercise/asthenia).
Measure: The change of the average VAS score from baseline to week 4 Time: week 4Description: At the end of week 2, week 4 and week 8, the average VAS score of main clinical symptoms in the past 1 week changed from baseline. VAS score measure is as same as the primary outcome.
Measure: The change of the average VAS score from baseline to week 2, and week 8 Time: week 2 and week 8Description: At the end of week 2, week 4 and week 8, the severity VAS score of main clinical symptoms in the past 1 week changed from baseline. VAS score measure is as same as the primary outcome.
Measure: The change of the severity VAS score from baseline to week 2, week 4 and week 8 Time: week 2, week 4 and week 8Description: At the end of week 2, week 4 and week 8, the average insomnia VAS score in the past 1 week changed from baseline. VAS score measure is as same as the primary outcome.
Measure: The change of the average insomnia VAS score from baseline to week 2, week 4 and week 8 Time: week 2, week 4 and week 8Description: At the end of week 2, week 4 and week 8, the average VAS score of sweating, mental fatigue, anorexia and nervousness in the past 1 week changed from baseline. VAS score measure is as same as the primary outcome.
Measure: The change of the average VAS score of sweating, mental fatigue, anorexia and nervousness from baseline to week 2, week 4 and week 8 Time: week 2, week 4 and week 8Description: At the end of week 2, week 4 and week 8, the average times of diarrhea and complete spontaneous bowel movement in the past 1 week changed from baseline.
Measure: The change of the average times of diarrhea and complete spontaneous bowel movement to week 2, week 4 and week 8 Time: week 2, week 4 and week 8Description: At the end of week 2, week 4 and week 8, the proportion of patients whose average and severity VAS scores of main clinical symptoms (except diarrhea and constipation) in the past 1 week changed from baseline decreased 50% and 75%. VAS score measure is as same as the primary outcome.
Measure: The proportion of patients with 50%/75% improvement of clinical symptoms to week 2, week 4 and week 8 Time: week 2, week 4 and week 8Description: At the end of week 2, week 4 and week 8, the walking distance of six-minute-walking test changed from baseline.
Measure: The change of the walking distance of six-minute-walking test from baseline to week 2, week 4 and week 8 Time: week 2, week 4 and week 8Description: At the end of week 2, week 4 and week 8, the lowest oxygen saturation of six-minute-walking test changed from baseline.
Measure: The change of the lowest oxygen saturation of six-minute-walking test from baseline to week 2, week 4 and week 8 Time: week 2, week 4 and week 8Description: At the end of week 2 and week 4, the proportion of patients in recovery of pulmonary function in all participants.
Measure: The proportion of patients in recovery of pulmonary function on week 2 and week 4 Time: week 2 and week 4Description: Lung CT shows complete absorption of inflammation.
Measure: The proportion of patients whose lung CT return to normal on week 4 Time: week 4Description: At the end of week 4 and week 8, the WHO Quality of Life-BREF (WHO QOL-BREF) score changed from baseline. The higher scores mean better outcome.
Measure: The change of the WHO QOL-BREF score from baseline to week 4 and week 8 Time: week 4 and week 8Description: At the end of week 4 and week 8, the Self-Rating Anxiety Scale (SAS) score changed from baseline. The higher scores mean worse outcome.
Measure: The change of the SAS score from baseline to week 4 and week 8 Time: week 4 and week 8Description: At the end of week 4 and week 8, the Self-Rating Depression Scale (SDS) score changed from baseline.The higher scores mean worse outcome.
Measure: The change of the SDS score from baseline to week 4 and week 8 Time: week 4 and week 8Description: At the end of week 4, the blood C-reactive protein (CRP) value changed from baseline.
Measure: The change of the blood CRP value from baseline to week 4 Time: week 4Description: At the end of week 4, the blood lymphocyte count (LYMPH#) changed from baseline.
Measure: The change of the blood LYMPH# value from baseline to week 4 Time: week 4Description: At the end of week 4, the percentage of blood neutrophils (NEUT%) value changed from baseline.
Measure: The change of the blood NEUT% value from baseline to week 4 Time: week 4Description: Divide the patients into two subgroups (the non-elderly ≤ 40 years old; the elderly > 40 years old ) according to the baseline data. At the end of week 4, analyze the average VAS score of main clinical symptoms in the past 1 week changed from baseline in the two age groups. VAS score measure is as same as the primary outcome.
Measure: The change of the average VAS score from baseline to week 4 in different age groups. Time: week 4Description: Divide the patients into two subgroups (man; woman) according to the baseline data. At the end of week 4, analyze the average VAS score of main clinical symptoms in the past 1 week changed from baseline in the two gender groups. VAS score measure is as same as the primary outcome.
Measure: The change of the average VAS score from baseline to week 4 in different gender groups. Time: week 4Description: Divide the patients into four subgroups ( mild type；common type；severe type；critical type) according to the baseline data. At the end of week 4, analyze the average VAS score of main clinical symptoms in the past 1 week changed from baseline in the four clinical classification groups. VAS score measure is as same as the primary outcome.
Measure: The change of the average VAS score from baseline to week 4 in different clinical classification of COVID-19. Time: week 4As of March 18, 2020, COVID-19 cases were reported in approximately 195 countries. No specific therapeutic agents or vaccines for COVID-19 are available. Several therapies, such as remdesivir and favipiravir, are under investigation, but the antiviral efficacy of these drugs is not yet known. The use of convalescent plasma (CP) was recommended as an empirical treatment during outbreaks of Ebola virus in 2014. A protocol for treatment of Middle East respiratory syndrome coronavirus (MERS-CoV) with CP was established in 2015. This approach with other viral infections such as SARS-CoV, H5N1 avian influenza, and H1N1 influenza also suggested that transfusion of CP was effective. In previous reports, most of the patients received the CP by single transfusion. In a study involving patients with pandemic influenza A(H1N1) 2009 virus infection, treatment of severe infection with CP (n = 20 patients) was associated with reduced respiratory tract viral load, serum cytokine response, and mortality. In another study involving 80 patients with SARS, the administration of CP was associated with a higher rate of hospital discharge at day 22 from symptom onset compared with patients who did not receive CP. Accordingly, these findings raise the hypothesis that use of CP transfusion could be beneficial in patients infected with SARS-CoV-2. The objective of this study is to describe the initial clinical experience with CP transfusion administered to severe COVID-19 patients. The primary endpoint of this trial would be to assess the tolerability, efficacy, and dose-response of CP in severe COVID-19 patients. The secondary endpoint would be to assess the clinical and laboratory parameters after therapy, in-hospital mortality, length of hospital stay, reduction in the proportion of deaths, length of ICU stay, requirement of ventilator and duration of ventilator support. All RT-PCR positive cases with features of severe infection will be enrolled in this study. Apheretic CP will be collected from a recovered patient (consecutive two RT-PCR samples negative) between day 22 to 35 days of recovery and those with the antibody titre above 1:320. This RCT will consist of three arms, a. standard care, b. standard care and 200 ml CP and c. standard care and 400 ml CP as a single transfusion. Twenty (20) patients will be enrolled for each arm. Randomization will be done by someone not associated with the care or assessment of the patients by means of a random number table. Allocations will be concealed in sequentially numbered, opaque, sealed envelopes. Clinical parameters [fever, cough, dyspnea, respiratory rate, PaO2/ FiO2 level, pulse, BP, the requirement of O2, and others] will be recorded before and after CP. Laboratory parameters such as complete blood count, CRP, chest X-ray, SGPT, SGOT, S. Ferritin, and serum antibody titre will be measured before and after transfusion. Allergic or serum sickness-like reactions will be noted and adjusted with outcome. Laboratory tests including RT-PCR will be done at BSMMU virology and laboratory medicine department. Apheretic plasma will be collected at the transfusion medicine department of SHNIBPS hospital, ELISA, antibody titre will be done at CMBT, and patients will be enrolled at DMC and MuMCH. All necessary screening tests will be done before transfusion. Graphpad Prism v 7.0 will be used for analysis. One way ANOVA test, a non-parametric Mann-Whitney test, and a Kruskal-Wallis test will be performed to compare the arms. For parametric outcomes, the investigators will compare the odds ratios across the pairs.
Description: % of patients died after enrolment
Measure: Proportion of In-hospital mortality Time: 7 daysDescription: Time to death in hours after enrolment
Measure: Time to death Time: 7 daysDescription: Temperature in degree Fahrenheit at Day 0, 1, 3, 7
Measure: Fever Time: 7 daysDescription: Respiratory rate per minute at Day 0, 1, 3, 7
Measure: Respiratory distress Time: 7 daysDescription: Saturation of oxygen in % at Day 0, 1, 3, 7
Measure: Saturation of oxygen Time: 7 daysDescription: Blood pressure in mm of Hg at Day 0, 1, 3, 7
Measure: Blood pressure Time: 7 daysDescription: Oxygen requirements in liter/min at Day 0, 1, 3, 7
Measure: Oxygen requirement Time: 7 daysDescription: CRP level in mg/litre
Measure: C-reactive Protein Time: Day 0, 3 and 7Description: Serum Ferritin level in ng/ml
Measure: Ferritin Time: Day 0, 3 and 7Description: Serum SGPT level in I/U
Measure: SGPT Time: Day 0, 3 and 7Description: Serum SGOT level in I/U
Measure: SGOT Time: Day 0, 3 and 7Description: Duration of ICU stay in days
Measure: ICU stay Time: 14 daysDescription: Requirement of ventilator support in hours
Measure: Ventilator support Time: 14 daysDescription: Duration of hospital stay in days
Measure: Hospital stay Time: 14 daysDescription: % of patients developed early transfusion reaction like fever, sweating, rash, abdominal pain, urticaria, vomiting, wheezing, chest tightness and hypotension
Measure: Proportion of Transfusion reaction Time: 24 hoursScientists and medical workers all around the world were running out of time to manage COVID-19. Several studies have been done to understand the disease and ultimately to find possible treatment. Based on those studies, one of the potential treatment was antibody transfer from recovered COVID-19 patients. Passive antibody transfer was a fast and easy choice. The rational use of antibody from the patient's plasma is a natural neutralizing protein to the cell-infected virus and could possibly slow the active infection down. Investigators initiate an intervention study with purposes to produce quality convalescent plasma from the recovered patients, define the safety of plasma for human use and as an alternative treatment to improve the clinical outcomes of severe COVID-19 patients. The study hypothesis is convalescent plasma is safe and could possibly improve outcome of severe (non-critical) COVID-19 patients. This research will conduct the plaque reduction neutralizing test (PRNT) of recipient blood in vitro. The plasma will be collected in the blood transfusion unit (BTU) in Gatot Soebroto hospital. The storage, testing, transfer, and transfusion of eligible convalescent plasma are the authority of Gatot Soebroto BTU. PRNT and plasma antibody titer measurement from donor plasma will be conducted at Eijkman Institute of Molecular Biology. Investigators enroll approximately 10 patients consecutively, who will be admitted at Gatot Soebroto hospital. Baseline demographic characteristics of samples are recorded. Clinical dan laboratory data will be measured before and after plasma transfusion periodically. The measured variables are pharmacological therapy (antivirus, antibiotics, steroids), invasive oxygen therapy, oxygen index, sequential organ failure assessment (SOFA) score, and laboratory parameters such as leukocyte count, blood chemical panel include liver and renal function, C-reactive protein, procalcitonin, IL-6 and immunoglobulin titer of the recipient and also chest X-ray evaluation. The potential expected risk of plasma transfusions is transfusion reaction (immunological or non-immune related) and transferred foreign pathogen. Investigator will report and treat all adverse events after plasma transfusion has been done. A severe adverse event (SAE) will also report in a special form to sponsor and data safety monitoring board (DSMB). There is theoretically antibody-dependent enhancement (ADE) mechanism from COVID-19 whom will receive plasma transfusion to progress to severe immune response. This preliminary study is supposed to provide supporting data and experience of plasma processing to a larger study in the near future.
Description: PNRT50
Measure: Plaque reduction neutralization test (PNRT) Time: day 7 after first transfusionDescription: Change of D-dimer compared between pre and post transfusion
Measure: D-dimer Time: day 1,4,7,14 after first transfusionDescription: Change of CRP compared between pre and post transfusion
Measure: C-Reactive Protein (CRP) Time: day 1,4,7,14 after first transfusionDescription: Change of INR compared between pre and post transfusion
Measure: International Normalized Ratio (INR) Time: day 1,4,7,14 after first transfusionDescription: Change of OI compared between pre and post transfusion
Measure: Oxygenation Index Time: day 1,4,7,14 after first transfusionDescription: Change of CXR with CXR covid score compared between pre and post transfusion
Measure: Chest X-ray Time: day 1,4,7,28 after first transfusionDescription: every adverse event that cause patient to die, prolonged hospitalization or worsening clinical stage of illness
Measure: severe adverse event Time: from day 0 to 14 days after plasma transfusionIn late 2019, a novel coronavirus (COVID-19) appeared in Wuhan, China. The various ways that humans will recover from COVID-19 infections is just starting to be observed and it is clear there will be a wide range of convalescent experiences. This phased protocol is designed to observe and study the convalescence and recoveries from acute COVID-19 infections. Phase A Surveying (Phase A) will enable people in the community that are convalescing from COVID-19 infections to be studied using telephone interviews and internet-based questionnaires. The objective of Phase A Surveying is to observe and describe the range of medical syndromes that occur in the wake of an acute COVID-19 infection. Participants are required to be within the first six months of their recovery and have documentation of a positive laboratory test for COVID-19. The data collected during Phase A will inform the nature of the patient populations to be evaluated in more detail. Phase B Evaluation (Phase B) will allow surveyed participants of research interest from Phase A to be invited to the NIH Clinical Center for a medical evaluation and to undergo a panel of standard research measurements. Each participant would be medically and psychologically characterized to best understand if their complaints can be attributed to known disorders. The observations made during Phase B will provide first insights into the range and character of the post-COVID-19 syndromes. Individuals found to have disorders being studied within the Division of Intermural Research at NIH will be appropriately referred. The data collected during Phase B will identify patient populations that may benefit from deep phenotyping research. Evaluated individuals of research interest may be invited back to the NIH Clinical Center from broad and deep research measurement during Phase C Deep Phenotyping (Phase C). The deep phenotyping methods employed will be synchronized with other NIH-approved deep phenotyping protocols to foster cross-phenotype comparison research with other medical syndromes, such as Myalgic Encephalomyelitis/Chronic Fatigue Syndrome and Gulf War Illness. Deep phenotyping characterizations would be used to generate scientific hypotheses for testing in future studies. Evaluated individuals with Post-COVID-19 syndromes of research interest may be invited to participate in Phase D Longitudinal Evaluation phase (Phase D). This would enable the observation of the natural history of Post-COVID convalescence and allow for exploration of the biological mechanisms underlying successful recovery and how recovery can go awry. Previous epidemics have created unique medical syndromes in the past. It seems possible that an unique POST-COVID 19 Syndrome or Syndromes may manifest from the global pandemic. If so, data from this protocol may be used to define the nature of any Post-COVID 19 Syndromes. If warranted, a Criteria Development phase will develop data-driven research consensus criteria for any Post-COVID 19 Syndromes. The results of this protocol will provide novel insights into COVID-19 convalescence and its potential outcomes. This current version of the protocol provides the details for Phase A of the study only. Additional phases will be detailed in planned protocol Amendments. Objectives: Primary Objective: Phase A: to observe and describe the range of medical syndromes that occur in the wake of an acute COVID-19 infection. Secondary Objectives: Phase A: To observe and describe recovery trajectories following an acute COVID-19 infection. Endpoints: Outcome measures: Phase A: The number and severity of persistent symptoms associated with COVID-19 convalescence. Collected data will be used to characterize different narratives of COVID-19 convalescence. Study Population: Phase A: 1000 adults who are within six months of their convalescence from an acute COVID-19 infection with documentation of a positive COVID-19 test. Description of Sites/Facilities Enrolling Participants: Phase A: All activities will be done using telephone interviews and internet-based questionnaires that participants will complete offsite. Study Duration: Participant Duration: Phase A: Participants will be invited to complete questionnaires for a period of three years.
Description: The number and severity of persistent symptoms associated with COVID-19 convalescence. Collected data will be used to characterize different narratives of COVID-19 convalescence.
Measure: Screening Phase Time: End of StudyBackground: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causes coronavirus disease 2019 (COVID-19). The global outbreak of COVID-19 is a major public health problem. COVID-19 causes a wide range of symptoms. These symptoms range from mild breathing problems to life-threatening problems or death. Some people have no symptoms. This study aims to learn how acute and late immune responses to COVID-19 lead to different outcomes. The immune system is the body s defense against germs, including viruses, that invade the body. Objective: To characterize the immune responses during and after SARS-CoV-2 infection and determine if there is any relationship to clinical course and outcome. Eligibility: People ages 0 99 who have confirmed or suspected SARS-CoV-2 infection, people who are not infected despite heavy exposure, and relatives of enrolled participants. Design: This is a sample collection protocol to receive send-in biological specimens for exploratory studies, including gene testing. Participants will not be seen at the NIH for study visits. Study staff will talk with participants health care providers to screen them for the study. Participants enrolled into the protocol will send samples and clinical information at least once and more often if the participant has COVID-19. All participants will provide blood samples and possibly stool. We may also ask for left over specimens from any medical procedures completed as part of medical care. The study staff will also request participants health care providers to complete a survey to collect demographic and medical data. Some of this information may need to be provided directly by the participant. Pregnant individuals are invited to participate and may be asked to give cord blood samples after delivery. Study findings that affect participants health may be shared with their health care provider. Depending on findings, participants may be contacted to take part in other NIH studies. ...
Description: These endpoints were chosen to provide in depth molecularmeasurements of a wide variety of innate and adaptive host immuneresponses to a novel pathogen in heterogenous patients. This is anexploratory hypothesis generating study to identify findings for validation in future studies. These endpoints are needed to better understand pathogenic mechanisms, improve prognostic tools, optimize existing therapies, and identify new targets for treatment.
Measure: Characterization of the dynamic changes of innate and adaptive immune responses during SARS CoV 2 infection and convalescence. Time: End of StudyDescription: These endpoints were chosen to provide in depth molecularmeasurements of a wide variety of innate and adaptive host immuneresponses to a novel pathogen in heterogenous patients. This is anexploratory hypothesis generating study to identify findings for validation in future studies. These endpoints are needed tobetter understand pathogenic mechanisms, improve prognostic tools, optimize existing therapies, and identify new targets for treatment.
Measure: Identification of genetic variants that are associated with either severe/lethal COVID-19 or resistance to SARS CoV 2 infection. Time: End of StudyDescription: These endpoints were chosen to provide in depth molecular measurements of a wide variety of innate and adaptive host immuneresponses to a novel pathogen in heterogenous patients. This is anexploratory hypothesis generating study to identify findings for validation in future studies. These endpoints are needed to better understand pathogenic mechanisms, improve prognostic tools, optimize existing therapies, and identify new targets for treatment.
Measure: Measurement of proinflammatory/anti inflammatory cytokines produced during SARS CoV 2 infection and convalescence, including the IFN signature response. Time: End of StudyDescription: These endpoints were chosen to provide in depth molecular measurements of a wide variety of innate and adaptive host immuneresponses to a novel pathogen in heterogenous patients. This is anexploratory hypothesis generating study to identify findings for validation in future studies. These endpoints are needed to better understand pathogenic mechanisms, improve prognostic tools, optimize existing therapies, and identify new targets for treatment.
Measure: Survey of other potential blood proteomic biomarkers of disease. Time: End of StudyDescription: These endpoints were chosen to provide in depth molecular measurements of a wide variety of innate and adaptive host immuneresponses to a novel pathogen in heterogenous patients. This is anexploratory hypothesis generating study to identify findings for validation in future studies. These endpoints are needed to better understand pathogenic mechanisms, improve prognostic tools, optimize existing therapies, and identify new targets for treatment.
Measure: Characterization of serological responses against SARS CoV 2, other viruses or microbiota, and host antigens. Time: End of StudyDescription: These endpoints were chosen to provide in depth molecular measurements of a wide variety of innate and adaptive host immuneresponses to a novel pathogen in heterogenous patients. This is anexploratory hypothesis generating study to identify findings for validation in future studies. These endpoints are needed to better understand pathogenic mechanisms, improve prognostic tools, optimize existing therapies, and identify new targets for treatment.
Measure: Characterization of intrapatient SARS-CoV-2 genetic variation andevolution during infection and convalescence. Time: End of StudyAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports